HOPKINTON, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals (NASDAQ:SBPH) today announced that Martin Driscoll, president and chief executive officer of Spring Bank Pharmaceuticals, will present at the East Coast IDEAS Investor Conference on May 18, 2017 at the Boston Park Plaza in Boston, Massachusetts. Spring Bank’s presentation is scheduled to begin at 10:00 a.m. EDT. The presentation will be webcast live and may be accessed at the conference website, www.IDEASConferences.com, or on the “Investors & Media” page of the company's website: http://www.springbankpharm.com. The webcast will also be archived on the “Investors & Media” page of the company’s website.
About IDEAS Investor Conferences
The mission of the IDEAS Conferences is to provide independent regional venues for quality companies to present their investment merits to an influential audience of investment professionals. Unlike traditional bank-sponsored events, IDEAS Investor Conferences are “Sponsored BY the Buyside FOR the Buyside” and for the benefit of regional investment communities. Conference sponsors collectively have more than $200 billion in assets under management and include: Adirondack Research and Management, Allianz Global Investors: NFJ Investment Group, Ariel Investments, Aristotle Capital Boston, Barrow Hanley Mewhinney & Strauss, BMO Global Asset Management, Constitution Research & Management, Inc., Fidelity Investments, First Wilshire Securities Management, Inc., Gamco Investors, Granahan Investment Management, Great Lakes Advisors, Greenbrier Partners Capital Management, LLC, GRT Capital Partners, LLC, Hodges Capital Management, Ironwood Investment Management, Keeley Asset Management, Luther King Capital Management, Marble Harbor Investment Counsel, Perritt Capital Management, Punch & Associates, Westwood Holdings Group, Inc., and William Harris Investors.
The IDEAS Investor Conferences are held annually in Boston, Chicago and Dallas and are produced by Three Part Advisors, LLC. Additional information about the events can be located at www.IDEASconferences.com.
If interested in attending or learning more about the IDEAS conferences, please contact Joe Noyons, (817) 778-8424, email@example.com.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus. SB 9200 has been designed to selectively activate within infected cells the cellular proteins, retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, which have been implicated in the body's immune response to viral infections. Spring Bank believes that SB 9200 may play an important role in antiviral therapy by modulating the body's immune response through its mechanisms of action to fight viral infections such as HBV. For more information, please visit: http://www.springbankpharm.com.
Chief Financial Officer
Spring Bank Pharmaceuticals Inc.